Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators

Jimin Xu, Shuizhen Shi, Gang Liu, Xuping Xie, Jun Li, Andrew A. Bolinger, Haiying Chen, Wenbo Zhang, Pei-Yong Shi, Hua Liu, Jia Zhou

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Sirt6 activation has emerged as a promising drug target for the treatment of various human diseases, while only limited Sirt6 activators have been reported. Herein, a series of novel pyrrolo[1,2-a]quinoxaline-based derivatives have been identified as potent and selective Sirt6 activators with low cytotoxicity. Sirt6-knockdown findings have validated the on-target effects of this class of Sirt6 activators. Docking studies indicate the protonated nitrogen on the side chain of 38 forms π-cation interactions with Trp188, further stabilizing it into this extended binding pocket. New compounds 35, 36, 38, 46, 47, and 50 strongly repressed LPS-induced proinflammatory cytokine/chemokine production, while 38 also significantly suppressed SARS-CoV-2 infection with an EC50 value of 9.3 μM. Moreover, compound 36 significantly inhibited the colony formation of cancer cells. These new molecules may serve as useful pharmacological tools or potential therapeutics against cancer, inflammation, and infectious diseases.

Original languageEnglish (US)
Article number114998
JournalEuropean journal of medicinal chemistry
Volume246
DOIs
StatePublished - Jan 15 2023

Keywords

  • Anti-SARS-CoV-2
  • Anti-inflammation
  • Deacetylation
  • Drug discovery
  • Sirt6 activator

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators'. Together they form a unique fingerprint.

Cite this